Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

UK Breast Cancer Deaths Plummet

By Drug Discovery Trends Editor | August 12, 2010

LONDON (AP) – The rate at which women died from breast cancer dropped faster in Britain than in any other major European country during the last two decades, according to new research.

In previous studies, Britain has often ranked last among Western Europe for cancer survival rates. The U.K. does not spend as much money on new cancer drugs or other treatments as other countries including France and Germany.

In a study published online in the medical journal BMJ, European researchers analyzed data from the World Health Organization, looking for changes in the breast cancer death rates in 30 European countries from 1980 to 2006.

Among countries including France, Finland and Sweden, the death rate from breast cancer dropped by 10 to 16 percent. In the U.K., it fell by more than 30 percent. The authors said the decreasing death rates could be due to wider breast cancer screening and more targeted treatments.

In an accompanying commentary, Valerie Beral and Richard Peto of the University of Oxford wrote that incomplete records may have led to previously “misleading claims about the supposed inferiority of U.K. cancer treatment.”

Because cancer registration isn’t mandatory in the U.K., many cancer patients may only be picked up shortly before they die, giving the impression they only survive for a short time. Beral and Peto said the rapid drops in Britain’s cancer death rates appear valid.

Date: August 11, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50